Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Diabetes Health Reference Charts
Insulin Archives
Print | Email | Share | Comments (0)

Massive-Scale Study Coming Up To Determine If Major Diabetes Drugs Will Offset Type 2 and Heart Disease


Nov 1, 2001

Novartis Pharma AG, of Basel, Switzerland, announced the launch of a massive-scale diabetes prevention trial aimed at finding out if taking a Starlix (nateglinide) or Diovan (valsartan) over a long period of time will offset diabetes and heart disease. The trial will be conducted on individuals with impaired glucose tolerance (IGT) who are at high risk for cardiovascular disease.

Entitled NAVIGATOR (Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research), the four-arm study will involve 7,500 subjects from 600 to 800 research centers in 40 different countries. Participants will be 50 years of age or older with at least one type of cardiovascular disease, or at least 55 with at least one risk factor for heart disease. Subjects will be given either Starlix (60 mg before meals) or Diovan (160 mg daily), or both, or a placebo. In the first of two phases, the effect of Starlix and Diovan on the progression of diabetes will be studied for three years. In the second phase, researchers will examine the effect of the drugs on cardiovascular disease.

The protocol for the study is currently under review by the Food and Drug Administration.

"With as many as one in seven people over 40 being affected by IGT, it is essential that we evaluate strategies to improve the outlook of people with this condition," said Thomas Ebeling, CEO of Novartis Pharma AG, in the company's press release.

"The NAVIGATOR trial, which is nearly twice the size of any comparable trial, will show us whether restoration of early phase insulin secretion and improvements in insulin sensitivity can arrest decline to type 2 diabetes and prevent cardiovascular disease in this high-risk group," said Rury Holman, of University of Oxford, UK, one of the trial's lead investigators.

Starlix is an oral drug used to treat post-meal hyperglycemia. Diovan is an angiotensin II receptor blocker used to treat high blood pressure.


Categories: Diabetes, Diabetes, Food, Heart Care & Heart Disease, Insulin, Type 2 Issues



You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.